

# PUBLIC HEALTH AND THE EYE

JOHANNA SEDDON AND DONALD FONG, EDITORS

## Obesity and Eye Diseases

Ning Cheung, MBBS,<sup>1,2</sup> and Tien Y. Wong, FRANCO, FRCSE, PhD<sup>1,3</sup>

<sup>1</sup>Centre for Eye Research Australia, University of Melbourne, Victoria, Australia; <sup>2</sup>Royal Melbourne Hospital, Victoria, Australia; and <sup>3</sup>Singapore Eye Research Institute, National University of Singapore, Singapore

**Abstract.** The prevalence of obesity has reached epidemic proportions in many countries. Although its impact on overall health is well documented, less is known about the ocular manifestations of obesity. Among different eye diseases, obesity has been linked with age-related cataract, glaucoma, age-related maculopathy, and diabetic retinopathy. Numerous population-based and prospective studies support an association between obesity and risk of age-related cataract. However, the nature and strength of these associations, particularly with the different cataract subtypes, remains to be determined. There is strong evidence that obesity is associated with elevated intraocular pressure, but there is no convincing data to support a more direct association between obesity and glaucomatous optic neuropathy. Studies to date have not found a consistent pattern of association between obesity and risk of age-related maculopathy or diabetic retinopathy. Thus, although obesity may be a risk factor for many ocular conditions, the present literature is inadequate to establish any convincing associations. Furthermore, whether weight loss reduces the risk of eye diseases remains unresolved. Because of the potential public health impact of obesity, there is a greater need to understand its ocular effects. (*Surv Ophthalmol* 52:180–195, 2007. © 2007 Elsevier Inc. All rights reserved.)

**Key words.** age-related maculopathy • body mass index • cataract • eye disease • glaucoma • obesity • pseudotumor cerebri • retinal artery occlusion • retinal vein occlusion • retinopathy

### Introduction

Obesity is a major public health problem, with prevalence increasing at staggering rates in many countries.<sup>50,51,54,55,77,85,97,98</sup> The World Health Organization (WHO) defines obesity as a body mass index (BMI) of 30 kg/m<sup>2</sup> or greater, and overweight as individuals whose BMI falls between 25 kg/m<sup>2</sup> and 29.9 kg/m<sup>2</sup> (World Health Organization: Controlling the global obesity epidemic. Geneva: World Health Organization, 2002). Different classifications are used for some specific populations, such as Asians and children. In Asian populations, it has been proposed that a BMI of 25 kg/m<sup>2</sup> or

greater should be classified as obesity.<sup>98</sup> In children, BMI is classified according to percentiles for age and sex, and children with BMI higher than 95th percentiles for age and sex may be considered as overweight.<sup>30,39,133</sup>

Obesity affects a wide spectrum of age groups, from the young<sup>39,133</sup> to the elderly.<sup>104</sup> In the United States, the prevalence of obesity was 30% in 1999–2000,<sup>51</sup> with 65% of adults, and 10–15% of children and adolescents, categorized as overweight or obese.<sup>77,81</sup> The current International Obesity Task Force estimates suggest at least 1.1 billion people are overweight worldwide, and 312 million of them

are obese (World Health Organization/International Association: Redefining obesity and its treatment. Available at [www.idi.org.au/obesity\\_report.htm](http://www.idi.org.au/obesity_report.htm)).

The medical consequences of obesity are numerous. It is an established risk factor for many systemic diseases including coronary heart disease, type 2 diabetes mellitus, hypertension, stroke, dyslipidemia, osteoarthritis, and sleep apnea.<sup>43,69,77,123,155</sup> Obesity has also been associated with certain types of cancers.<sup>12,20</sup> One study estimated that obesity is responsible for approximately 40% of endometrial cancers, 25% of renal cancers, and 10% each of colonic and breast cancers.<sup>12</sup> Other obesity-associated comorbidities include polycystic ovary syndrome, fatty liver, as well as depression secondary to social stigmatization and discrimination.<sup>123</sup>

The impact of obesity on health is widespread, and the deleterious effects of obesity on the cardiovascular and metabolic systems are well known.<sup>77</sup> Less well documented, however, are the potential ocular effects of obesity. Obesity has recently been reported to be negatively associated with visual acuity,<sup>10</sup> but the ocular conditions underlying this association and the potential implications are unclear. Among different eye diseases, obesity has been associated with cataract,<sup>1,21,53,63,86,94,107,108,121,129,168,211,222</sup> age-related maculopathy,<sup>2,28,167,173</sup> diabetic retinopathy,<sup>8,24,83,114,171,207</sup> and glaucoma.<sup>60,127,225</sup> However, these associations have not been consistently documented. The purpose of this article is to review the potential ocular effects of obesity.

## Obesity and The Eye

### OBESITY AND CATARACT

Obesity has been proposed to be a risk factor for cataract development, though the exact underlying mechanisms are unclear. The relationship between obesity and cataract has been investigated in many epidemiological studies,<sup>10,21,22,53,63,74,86,94,107,108,121,126,129,144,168,197,211,222</sup> but the findings are not universally consistent (Table 1). The strongest evidence is based on prospective data from several large population-based studies demonstrating positive association between obesity and cataract.<sup>63,73,86,107,168,211</sup> In 1995<sup>63</sup> and 2000,<sup>168</sup> the Physicians' Health Study, a randomized trial of 22071 healthy male American physicians aged 40–84 years, reported both overall obesity, measured as BMI, and abdominal adiposity, measured as waist-to-hip ratio (WHR), as independent risk factors for cataract. It was found that at any given level of BMI, a 2-unit higher level predicted a 12% increase risk of cataract.<sup>63</sup> The Nurses' Health Study, a large pro-

spective study of female nurses in 1993, also found a higher rate of cataract surgery for women with BMI levels of 23 or greater compared to women with lower levels.<sup>73</sup> Subsequently, the Nurses' Health and the Health Professionals Follow-up Study generated further results, reporting that obesity increases risk of cataract overall, but in particular, of posterior subcapsular (PSC) type, even after adjusting for variables such as smoking, age, and diabetes.<sup>211</sup> Prospective data from the Framingham Eye Study also demonstrate an independent association between greater BMI and higher incident of cortical and PSC opacities.<sup>86</sup> Further support on the positive association between obesity and cataract is derived from cross-sectional data from other population-based,<sup>1,21,94,121,129,222</sup> and hospital-based studies,<sup>126,197</sup> although not all studies have been consistent. For example, using standardized photography to grade lens opacities, the Beaver Dam Eye Study, a cohort study of almost 5,000 white Americans, found no significant associations of obesity with either incident cataract or cataract extraction at the baseline or the 5-year follow-up examination.<sup>108,110</sup> Nonetheless, 10-year prospective data from this study showed an association between higher BMI and increased risk of PSC cataract in persons without diabetes.<sup>107</sup>

There have also been inconsistencies regarding the types of cataract associated with obesity in these studies. Cortical and PSC cataracts have been most consistently associated with obesity.<sup>1,21,121,129,222</sup> Among these studies, the Barbados Eye Study in African Americans found higher WHR to be associated with cortical opacities.<sup>129</sup> The Blue Mountain Eye Study in white Australians suggested that obese persons (BMI of 30 kg/m<sup>2</sup> or greater) have about half- and two-fold increase risk of having cortical and PSC cataracts respectively.<sup>222</sup> In the Age-Related Eye Disease Study (AREDS), both higher BMI and weight gain were found to have significant association with moderate cortical cataract, independent of age and sex.<sup>1</sup> But this association was not statistically significant in the fully adjusted model.

Several plausible pathophysiological mechanisms have been proposed to explain the association of obesity and cataract. One theory suggests that leptin, a 16-kDa pleiotropic cytokine expressed and secreted mainly by adipocytes,<sup>227</sup> is involved in the molecular mechanisms underlying cataract formation.<sup>64</sup> Studies have discovered that individuals with obesity likely exhibit hyperleptinemia and leptin resistance.<sup>59,78,79,149</sup> Leptin has also been found to increase accumulation of reactive oxygen species in various cellular models.<sup>14,219</sup> This link between obesity, hyperleptinemia, and increased

TABLE 1

*Population-based Studies Investigating the Relationship between Obesity and Cataract*

Study					
Year	Type	Population	Definition of Cataract	Summary of Main Findings	Reference
2002	P	The Nurses' Health Study and the Health Professionals Follow-up Study	Incident cataract extractions	Higher BMI associated with overall cataract overall (36%, RR 1.36; 95% CI 1.23–1.49) after adjustment for smoking, age and lutein/zeaxanthin intake, and with PSC cataract (RR 1.68 (95% CI 1.30–2.17), after adjusting for diabetes.	211
2000	P	The Physicians' Health Study	Incident cataract and cataract surgery	Higher BMI (RR 1.25) and WHR (RR 1.31) associated with cataract, after adjustment for cigarette smoking, alcohol consumption, exercise, multivitamin use, diabetes, and systolic blood pressure.	168
1995	P	The Physicians' Health Study	Incident cataract or cataract extraction	Higher BMI (RR 2.1) associated with incident cataract. Stronger associations noted for PSC and nuclear cataracts.	63
1998	P	The Framingham Eye Study	Eye examination and lens photographs	Higher BMI associated with cortical (OR 3.24) and PSC (OR 1.24) opacities after adjustment for age, sex, education, diabetes, and smoking.	86
1993	P	The Nurses' Health Study with 5 year follow-up	Incident cataract extraction	Higher BMI associated with higher rate of cataract extraction in women.	73
1998	P	The Beaver Dam Eye Study Cohort	Eye examination, lens photography	Higher BMI associated with increased risk of PSC cataract in persons without diabetes.	107
2001	C	The Age-Related Eye Disease Study (AREDS)	Eye examination Lens photography	Higher BMI (OR 1.40) and weight gain (OR 1.51) associated with moderate cortical cataract after adjustment for age and sex.	1
2001	C	The Beaver Dam Eye Study	Eye examination Lens photographs	WTH ratio was more strongly associated with cortical and PSC opacities than BMI, but the relationships not significant.	108
1997	C	The Beaver Dam Eye Study	Incident cataract extraction	BMI not associated with cataract extraction.	110
2003	C	The Blue Mountains Eye Study	Lens photographs	Higher BMI associated with cortical (OR 1.6) and PSC cataract (OR 2.1).	222
1999	C	The Barbados Eye Study	Lens Opacities Classification System II on eye examinations	Higher WHR associated with cortical opacities after adjustment for age (OR 1.36).	129
2003	C	The Nurses' Health Study	Lens Opacification Classification System III	Higher BMI (OR 2.5) and abdominal adiposity (OR 2.3) associated with PSC opacities, but not with nuclear and cortical cataract.	94
1999	C	The Salisbury Eye Evaluation project	Eye examinations Lens photography Wilmer grading scheme	Higher BMI associated with cortical cataract (adjusted OR 1.26), but lower BMI (OR 1.13) associated with nuclear cataract, after adjustment for age, race, sex, stature, alcohol consumption, and average annual ultraviolet blue exposure. BMI not associated with PSC opacities.	21
2003	C	The Tanjong Pagar Survey	Eye examinations Lens Opacity Classification System III	Lower BMI associated with any cataract (OR 2.3) and cortical cataract (OR 1.8) after adjustment for age, sex and other factors.	53

(Continued)

TABLE 1  
Continued

Study			Definition of Cataract	Summary of Main Findings	Reference
Year	Type	Population			
2005	C	The Shihpai Eye Study	Lens Opacities Classification System III grade of more than 2	Higher BMI associated with lower risk of nuclear (OR 0.73) and higher risk of cortical 1.52 opacities. No association with PSC opacity.	<sup>121</sup>
1982	C	Survey from 1269 participants in Punjab	Incident cataract survey	Lower body weight associated with higher prevalence of cataract.	<sup>22</sup>

BMI = body mass index; PSC = posterior subcapsular; WTH = waist-to-hip; OR = odds ratio; RR = relative risk; CI = confidence interval; P = prospective; C = cross-sectional.

oxidative stress has been further reinforced by a subsequent study revealing a strong positive association between BMI and systemic oxidative stress as determined from creatinine-indexed urinary concentrations of 8-epi-prostaglandin F2 $\alpha$ .<sup>103</sup> In addition, recent studies have proposed that oxidative stress may play an important pathogenic role in cataract formation.<sup>11,58,90,161,187-190</sup> In view of these links, hyperleptinemia associated with obesity may promote cataract formation. Nevertheless, the exact mechanism by which leptin contributes in the process of cataractogenesis is still unclear. Apart from leptin, elevated levels of C-reactive protein and plasma fibrinogen were also found in obese individuals,<sup>32,52,71,209</sup> and recently these markers of inflammation, such as fibrinogen, have been suggested to have association with cataract.<sup>65,169</sup> Furthermore, obesity has also been linked to cataract by its associated complications such as diabetes,<sup>1,52,115,127,130,183</sup> glucose intolerance, insulin resistance,<sup>69</sup> hyperlipidemia, and hypertension. They are all known risk factors for cataract,<sup>74,96,101,129,197,211,222</sup> but the primary role of these factors in cataractogenesis is less clear.

Although the majority of data suggest that higher BMI is associated with cataract, there has been a body of literature that lower BMI may also be a risk factor for some forms of cataract,<sup>21,22,126</sup> particularly in non-white populations.<sup>53,121,144</sup> Among Chinese people in the Shihpai Eye Study in Taiwan, for example, whereas higher BMI was associated with cortical opacity, lower BMI was associated with nuclear opacity.<sup>121</sup> In the Tanjong Pagar Survey in Chinese Singaporeans, lower BMI was an independent risk factor for cataract, particularly for cortical cataract.<sup>53</sup> There has been no clear explanation for this pattern of associations. It has been suggested that lower BMI reflects poor nutritional status and malnutrition in developing countries is a potential risk factor for cataract.<sup>198</sup> However, not all Asian

data suggest this pattern, and a study in India found no association between lower BMI and age-related cataract.<sup>205</sup>

Finally, there is no evidence that weight loss prevents cataract formation. Although several studies have proposed that weight loss and reduction of abdominal obesity would likely lessen incidence and costs of cataract,<sup>96,168</sup> the efficacy of obesity treatment in reducing risk of cataract has never been evaluated in clinical trials.

In summary, based on the current data, obesity is likely associated with cataract. However, there is still controversy regarding which type of cataract is related to obesity. There are varying patterns and strengths of association for different cataract types, suggesting possible existence of distinct etiological pathways for the different types of cataracts.<sup>212</sup> The reason for the disparity of findings may also partly be due to racial/ethnic differences in population groups and use of different grading systems for cataract and lens opacities.

**OBESITY AND GLAUCOMA**

In contrast to cataract, there are fewer data addressing the relationship between obesity and glaucoma, although there have been several studies that have provided evidence in support of a positive association between obesity and intraocular pressure (IOP) (Table 2), the strongest risk factor for glaucomatous optic neuropathy (GON).<sup>9,66,99,127,140,185</sup>

Most epidemiological studies have been focusing on the association between obesity and IOP or ocular hypertension. Population-based data from several studies have demonstrated independent cross-sectional association between obesity and ocular hypertension.<sup>17,95,109,125,148,175,177,218,221</sup> The Beaver Dam Eye Study reported a significantly positive association of IOP with several factors

including BMI.<sup>109</sup> This was consistent with findings from a subsequent hospital-based study, indicating that ocular hypertension risk was significantly greater in persons with BMI of 30 or greater, independent of age and sex.<sup>95</sup> Studies of Asian populations generated similar results.<sup>125,146,175,221</sup> In a large population-based study of 25,216 Japanese aged 14–94 years, a positive association between obesity and ocular hypertension was evident in both longitudinal and cross-sectional analysis, even after controlling for age, sex, and blood pressure.<sup>146</sup> This was further reinforced by another large population-based study of Koreans.<sup>125</sup> Some studies further suggest that the association between obesity and ocular hypertension may reflect underlying association between insulin resistance and ocular hypertension, as the association between obesity measures and IOP was not significant after adjustments for glucose and other confounders.<sup>152</sup>

On the contrary, only few studies have directly examined the association between BMI and GON. The limited data generated from these studies demonstrate noticeable inconsistency. Firstly, cross-sectional data from the Barbados Eye Study suggested some protective effect of higher BMI with risk of open-angle glaucoma.<sup>127</sup> The analysis, however, only controlled for age and not other factors, and the possibility of incomplete adjustment for confounders cannot be excluded. Secondly, a hospital-based study, relying on review of medical records, reported that patients with higher BMI were more likely to have a clinical diagnosis of glaucoma on admission.<sup>225</sup> Lastly, in a case-control study, comparing persons with and without glaucoma, no statistically significant difference in BMI was identified.<sup>60</sup>

A clear pathophysiological explanation for the association of obesity with IOP and glaucoma is currently lacking. Both the ‘mechanical’ and ‘vascular’ etiology theories of glaucoma may be related to obesity. With regards to the mechanical theory,<sup>72</sup> obesity has been postulated to exert an effect on IOP by causing excessive intraorbital adipose tissue, increased blood viscosity, increased episcleral venous pressure, and impairment of aqueous outflow facility.<sup>17,166,176,177</sup> Furthermore, ocular hypertension has been associated with obesity-related systemic diseases such as hypertension,<sup>13,37,106,128,138,200,218</sup> diabetes,<sup>152</sup> dyslipidemia,<sup>95</sup> and insulin resistance.<sup>147,152,218</sup> Increased blood pressure may lead to an increased filtration fraction of the aqueous humor through elevated ciliary artery pressure,<sup>17,82,177</sup> and hyperglycemia may induce osmotic fluid shift into the intraocular space.<sup>141</sup> Both mechanisms can ultimately result in elevated IOP. On the other hand, the vascular theory suggests that eyes with inherently poor vascular supply to the

optic nerve head are more predisposed to damage by elevated or normal IOP.<sup>38,134</sup> Impaired vascular supply may be related to abnormal ocular blood flow and perfusion instability secondary to alternations in autonomic and endothelial function.<sup>16,49,68,70,75,100</sup> Obesity has been shown to cause both vascular endothelial dysfunction<sup>62,223</sup> and autonomic dysfunction, particularly in people with diabetes.<sup>132,135</sup> In addition, cellular factors, including neurotrophin deprivation, release of excitatory amino acids, and oxidative stress, have also been suggested to contribute to GON on the molecular level.<sup>18,46,61,93,145,153,154,159,165,229</sup> Among these, oxidative stress has recently gained intense interest.<sup>18,46,61,93,145,153,165,229</sup> Increased oxidative DNA damage was found in the trabecular meshwork of glaucoma patients,<sup>93</sup> and oxidative stress has been postulated to cause proteasome failure and induce human trabecular meshwork degeneration, leading to impairment of the ability of the tissue to modulate outflow resistance.<sup>18</sup> As discussed previously, hyperleptinemia, which is closely related to obesity, is associated with increased oxidative stress.<sup>14,31,59,78,79,103,149,219</sup> Therefore, theoretically, obesity-associated hyperleptinemia may cause an increase in systemic oxidative stress, priming the glaucoma pathogenetic cascade.<sup>165,229</sup>

The impact of weight loss on IOP and the development or progression of glaucoma has never been investigated. Although people with ocular hypertension may not develop glaucoma,<sup>105</sup> recent meta-analysis of several methodologically adequate trials revealed that primary prevention of glaucomatous visual field defects in patients with ocular hypertension by using topical pressure lowering agents seems to be effective.<sup>38,134</sup> This raises the possibility that weight reduction, with adjuvant medical therapy, in obese patients with raised IOP may help preventing the development and progression of GON.

In summary, there is considerable evidence from clinical studies to support an association between obesity with higher IOP. However, current evidence of a direct association between obesity and GON is weak. The possible pathogenic role of obesity in GON remains uncertain as most of the etiologic links are still at the hypothetical level. Further studies are warranted to clarify whether obesity is truly a risk factor for glaucoma.

#### OBESITY AND AGE-RELATED MACULOPATHY

Age-related maculopathy (ARM) remains a major blinding condition in the elderly, despite the introduction of several new treatment modalities, including photodynamic therapy,<sup>27,76,136,217</sup> novel

TABLE 2  
*Studies Investigating the Relationship between Obesity and Glaucoma or Intraocular Pressure*

Study		Population	Definition of Glaucoma	Summary of Main Findings	Reference
Year	Type				
1995	PB, C	The Barbados Eye Study	IOP Visual field defect optic disc damage	Higher BMI associated with lower risk of open-angle glaucoma (high vs. low BMI quartiles with OR 0.39) after adjustment for age.	127
1999	HB, C	288 control subjects 129 patients with glaucoma	Visual defects IOP	BMI not associated with glaucoma.	60
1994	HB, C	20,011 males 9,083 females	Medical records	Highest BMI associated with glaucoma.	225
2002	PB, C	13,212 healthy Koreans aged 20–70	IOP measurement by applanation tonometry	Higher BMI associated with higher IOP after controlling for age, sex, and mean blood pressure in men ( $p < 0.05$ ), but association not significant in women.	125
2000	PB, C	25,216 Japanese aged 14–94 years	IOP measurement by applanation tonometry	Higher BMI associated with higher IOP after adjustment for age, sex, and blood pressure in cross-sectional analysis (IOP 11.3 with BMI < 20 vs. IOP 12.2 with BMI $\geq 25$ ; $p < 0.0001$ ). Increased weight associated with higher IOP, even after adjustment for age, sex, initial BMI, initial blood pressure, and initial IOP in longitudinal analysis.	146
1997	PB, C	The Barbados Eye Study	IOP measurement by applanation tonometry	Higher BMI associated with higher IOP.	218
1992	PB, C	The Beaver Dam Study	IOP measurement by applanation tonometry	Higher BMI associated with higher IOP.	109
1986	PB, C	93,703 Japanese persons	IOP measurement by applanation tonometry	Higher obesity index associated with higher IOP.	177
2005	HB, C	943 healthy persons	IOP measurement by applanation tonometry	Insulin resistance indices showed positive associations with IOP, even after multiple adjustments. Abdominal obesity associates with higher IOP in men, but not in women, and not statistically significant after adjustments.	152
2003	HB, C	649 Japanese aged 29–79 years	IOP measurement by applanation tonometry	Higher BMI associated with higher IOP in both men and women after adjustment for alcohol consumption, cigarette smoking, habitual exercise and coffee consumption, with systolic blood pressure.	221
2001	HB, C	990 persons aged $\geq 40$ years old	IOP measurement by applanation tonometry with ocular hypertension defined as IOP $\geq 21$ mmHg	Higher BMI associated with ocular hypertension (OR $\geq 4.2$ ) after adjustment for age and sex.	95

BMI = body mass index; IOP = intraocular pressure; OR = odds ratio; PB = population-based; HB = hospital-based; P = prospective data; C = cross-sectional data.

pharmacological approaches to inhibit angiogenesis,<sup>34,47,67,170</sup> and the use of antioxidant supplement.<sup>27,88</sup>

The relationship between obesity and ARM has been investigated in several studies (Table 3).

Hirvelä and colleagues<sup>87</sup> were the first to observe a positive association between obesity and ARM. This association was subsequently supported by epidemiological data from several large population-based studies.<sup>36,108,167,184</sup> Prospective data from

TABLE 3  
*Studies Investigating the relationship between Obesity and Age-Related Maculopathy*

Type of Study		Population	Definition of Age-Related Maculopathy	Summary of Main Findings	Reference
Year	Type				
2001	PB, P	The Physician Health Study	Incident ARM	Higher BMI associated with incident visually significant dry ARM (rate ratio 2.15), after adjustment for age and cigarette smoking.	<sup>167</sup>
2005	HB, P	Age-Related Eye Disease Study (AREDS) 3,295 patients with baseline early/intermediate ARM	Fundus photographs	Higher BMI (OR 1.93) associated with geographic atrophy and risk for progression from early/intermediate to advanced ARM, after adjustment for age, sex, and treatment group.	<sup>28</sup>
2000	HB, P	AREDS	Color fundus photographs	Higher BMI associated with more advanced ARM.	<sup>2</sup>
2003	HB, P	366 persons aged > 60 years	Fundus photography	Higher BMI (RR 2.32) and larger abdominal circumference (RR 2.04) associated with progression to advanced ARM.	<sup>173</sup>
1998	PB, C	The Blue Mountains Eye Study	Retinal photographs Wisconsin Age-Related Maculopathy Grading System	Higher BMI (OR 1.78) and plasma fibrinogen level (OR 6.7) associated with ARM.	<sup>184</sup>
1996	PB, C	500 participants aged 70 or older	Fundus photographs or ophthalmoscopic findings	Higher BMI in men associated with higher prevalence of ARM in all age groups (48% for BMI $\geq$ 27.5 vs. 34% for BMI $\leq$ 27.5, $p = 0.019$ ).	<sup>87</sup>
2001	PB, C	The Beaver Dam Eye Study	Retinal photographs	Higher BMI associated with early (OR 1.59), but not late ARM in women, but not men.	<sup>108</sup>
2001	PB, C	The POLA Study 2,584 European aged 60–95	Eye examination and fundus photographs	Higher BMI associated with increased risk of late ARM (2.29-fold) and retinal pigmentary abnormalities (1.54-fold).	<sup>36</sup>

ARM = age-related maculopathy; BMI = body mass index; OR = odds ratio; RR = relative risk; CI = confidence interval; PB = population-based; C = cross-sectional data; P = prospective data.

the Physicians' Health Study demonstrated that the 15-year incidence for visually significant dry ARM was highest in obese men and lowest in men with normal BMI, even after controlling for age and cigarette smoking.<sup>167</sup> However, the study could not find any significant association between obesity and neovascular ARM, which was possibly due to a small number of cases in the studied population. The AREDS has reported cross-sectional association between higher BMI and more advanced ARM, as documented from fundus photographs.<sup>2</sup> A more recent report in 2005 among patients with baseline early or intermediate ARM showed that greater BMI

was significantly associated with incident geographic atrophy and progression to advanced ARM with visual impairment, even after controlling for multiple factors including age, sex, and treatment.<sup>28</sup> These findings are supported by cross-sectional data from the Blue Mountains Eye Study, although the Beaver Dam Eye Study only found this association in women but not in men.<sup>108</sup> The Pathologies Oculaires Liées à l'Age (POLA) Study of a large number of Europeans found that obese individuals have a two-fold increase in risk for developing late but not early ARM,<sup>36</sup> although adjustment for other variables such as smoking were not performed.

The pathophysiological mechanisms accountable for the probable association between obesity and ARM are unclear. ARM is a multifactorial disease with some common downstream pathophysiological pathways leading to the spectrum of retinal signs seen clinically.<sup>89,120,164,226</sup> Obesity has been hypothesized to be linked to some of these pathways. As discussed previously, obesity may increase systemic oxidative stress secondary to hyperleptinemia.<sup>14,31,59,78,79,103,149,219</sup> There is compelling evidence that oxidative stress plays an important role in the pathogenesis of ARM.<sup>120,164,186,226</sup> Oxidative damage to lipids in Bruch membrane appears to be important in the etiology of choroidal neovascular ARM.<sup>186</sup> In response to excessive oxidative stress, the RPE cells may detach and migrate into the subretinal space or outer retina and secrete excessive vascular endothelial growth factor (VEGF), eliciting invasion of neovascularization in Bruch membrane.<sup>186</sup> Given this, obesity may have a role in the development of ARM because of its associated hyperleptinemia-induced oxidative stress. Nevertheless, a study examining the association of plasma leptin with ARM found paradoxical results; plasma leptin was negatively correlated with severity of ARM, after controlling for age, sex, and BMI. It was suggested by the authors that reduced leptin levels could result in loss of its lipidostatic function in cellular level, leading to an increased intracellular fatty acid accumulation within the lesions found in ARM patients.<sup>44</sup> Studies has also shown that plasma fibrinogen and other markers of inflammation (e.g., C-reactive protein) may be associated with late ARM,<sup>184</sup> suggesting that inflammation may play a role in ARM development. Plasma fibrinogen and C-reactive protein, for example, are elevated in both adults and children with obesity,<sup>6,206</sup> and may therefore be a potential link between obesity and ARM. Finally, other proposed risk factors for ARM, including hypertension<sup>2,36,91,92,116</sup> and hyperlipidemia,<sup>112,210</sup> are also well-known conditions associated with obesity, raising the possibility that obesity may cause ARM by secondary effects from its associated complications.

Apart from an association between BMI and ARM, central obesity, as defined by the waist circumference or WHR, has also been found to increase risk of progression to advanced ARM in one study,<sup>173</sup> although not in another.<sup>143</sup> As with the association of BMI and cataract, there are also some conflicting data, based on a smaller number of studies, indicating that lean body mass may increase risk of ARM.<sup>115,167,183</sup>

In summary, there is considerable evidence that supports an association between obesity and ARM. The nature of this association with the different

types of ARM and the role of weight loss in preventing the development or slowing the progression of ARM, however, remains to be determined.

#### OBESITY AND DIABETIC RETINOPATHY

The association between obesity and diabetic retinopathy has been investigated in several studies. Most,<sup>8,35,113,203,207,213,228</sup> but not all,<sup>23,41,114,124,150</sup> studies have documented a relationship between higher BMI and increased risk of retinopathy (Table 4). Few of these studies, however, have prospective data.<sup>8,24,83,114</sup> A study in Sweden examined 582 young (aged 15–34) individuals with diabetes (79% type 1 diabetes) with 10-year follow-up, and found that individuals with higher BMI developed retinopathy at earlier stage.<sup>83</sup> The EURODIAB Prospective Complications Study of 764 individuals with type 1 diabetes after more than 7 years of follow-up reported WHR as an independent risk factor for diabetic retinopathy.<sup>24</sup> However, conflicting data were generated in the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR).<sup>113,114</sup> Although obesity (BMI > 31.0 kg/m<sup>2</sup> for men and 32.1 kg/m<sup>2</sup> for women) was found to associate with progression and severity of retinopathy, these associations were not statistically significant and were limited to only individuals with older-onset insulin-independent diabetes.<sup>113</sup> On the other hand, for those who were underweight (BMI < 20 kg/m<sup>2</sup>), a threefold increase in risk of developing retinopathy was demonstrated.<sup>114</sup> Underweight has been suggested to be a marker of the more “severe” phase of diabetes, or an indicator of late-onset type 1 diabetes.<sup>113</sup>

There are new data that show obesity is associated with retinopathy signs in the general population and non-diabetic persons. In the Hoorn Study in the Netherlands, WHR was also independently associated with a number of incident retinopathy signs, including retinal hemorrhages, microaneurysms, hard exudates, and cotton-wool spots in the non-diabetic general population, although the association with BMI failed to achieve statistical significance.<sup>208</sup>

The underlying pathophysiological mechanisms of the possible association between obesity and retinopathy are not understood.<sup>40</sup> Epidemiological data from various studies have identified hyperlipidemia<sup>25,26,29,33,48,111,117,147,150,193</sup> and hypertension<sup>110,119,192,196</sup> as risk factors for diabetic retinopathy. Both conditions are common risk factors of obesity. In fact, metabolic syndrome, encompassing these conditions, has also been shown to be associated with retinopathy.<sup>213</sup>

TABLE 4  
*Studies Investigating the relationship between obesity and Diabetic Retinopathy*

Study					
Year	Type	Population	Definition of Diabetic retinopathy	Summary of Main Findings	Reference
2003	PB, P	The Hoorn Study	Ophthalmoscopy and fundus photography	Higher WHR (OR 8.67) associated with retinopathy, but not for BMI.	208
2003	PB, P	Diabetes Incidence Study in Sweden (DISS) (79% type 1 diabetes)	Retinal photographs	Higher BMI associated with earlier development of retinopathy (RR 1.11).	83
2001	PB, P	EURODIAB Prospective Complications Study (persons with type 1 diabetes)	Retinal photographs	Higher WHR (OR 1.32) associated with diabetic retinopathy.	24
1986	PB, P	1,031 persons with diabetes mellitus	Incident diabetic retinopathy Ocular Examination	Obesity associated with increased risk of retinopathy (hazard ratio 2.01).	8
2001	PB, C	Diabetes Control and Complications Trial (DCCT)	Ocular Examination	Higher BMI (OR 1.11) associated with diabetic retinopathy after adjustment for metabolic control.	228
2002	PB, C	The Hoorn Study	Ophthalmologic examination and fundus photography	Higher BMI (OR 1.3) associated with retinopathy.	207
1984	PB, C	Wisconsin Epidemiologic Study of Diabetic Retinopathy	Ocular examination and retinal photography	Small body mass associated with more severe retinopathy.	114
1998	PB, C	911 of 6,553 participants from survey on the Indian Ocean island of Mauritius	Retinal photographs with grading according to modified Airlie House criteria	Lower BMI associated with retinopathy.	41
2005	HP, C	156 persons with diabetes mellitus	Ocular examinations	Higher BMI associated with increased prevalence of retinopathy (40.8% in BMI $\leq$ 25, 63.4% in BMI 26–29.9, 63.6% in BMI $\geq$ 30).	101

BMI = body mass index; OR = odds ratio; RR = relative risk, CI = confidence interval; PB = population-based; HP = hospital-based; P = prospective data; C = cross-sectional data.

However, there is also evidence that obesity may have a more direct role in the development of retinopathy. Several pathogenetic theories of diabetic retinopathy exist based on the potential roles of aldose reductase activity, vasoproliferative factors, oxidative stress, platelet function and blood viscosity. Of these, vasoproliferative factors, such as the vascular endothelial growth factor (VEGF), have recently gained intense interest. The concentration of VEGF has been found to be higher in the vitreous of eyes with proliferative diabetic retinopathy.<sup>5</sup> Serum angiogenic factors, including VEGF, have been observed to be elevated in obese human.<sup>142,179</sup> These findings provide a potential link between obesity and proliferative diabetic retinopathy. Moreover, oxidative stress has also been suggested to

contribute in the pathogenesis of diabetic retinopathy,<sup>19,156</sup> possibly by inducing over-expression of VEGF and cause features of diabetic retinopathy including retinal neovascularization and macular edema.<sup>19,178</sup> Finally, as discussed in previous sections, obesity may increase oxidative stress because of its associated hyperleptinemia.<sup>14,31,59,78,79,103,149,219</sup> High levels of plasma leptin have been found to relate to both hypertensive<sup>4,172,194,203</sup> and diabetic retinopathy.<sup>57,203</sup> Detailed pathophysiological pathways leading to hypertensive retinopathy has been described elsewhere,<sup>215</sup> but leptin has been postulated to worsen hypertension by activation of the sympathetic nervous system,<sup>4</sup> accelerating the development of hypertensive retinopathy.<sup>80</sup> Positive association between severity of hypertensive

retinopathy and plasma leptin, independent of BMI, has been reported.<sup>204</sup> Apart from leptin, other adipocytokines have also been investigated, but the evidence to support their roles in the pathogenesis of retinopathy is currently weak.<sup>42,45,56,137,220</sup>

The impact of weight loss, particularly in obese individuals, on regression of retinopathy has been inadequately investigated.<sup>174,195</sup> Lifestyle changes, such as weight loss, has been advocated as a key factor in helping prevent diabetes and to delay diabetic complications including retinopathy in susceptible patients.<sup>174</sup> However, patients with type 1 diabetes and anorexia nervosa with weight loss have also been observed to have higher risk of developing early retinopathy.<sup>195</sup> In spite of the insufficient data, it is generally accepted that weight reduction should be advised in obese diabetic individuals to reduce the risk of cardiovascular disease<sup>118,180–182,191,201,202,216</sup> and possibly diabetic retinopathy.<sup>224</sup>

#### OBESITY AND OTHER EYE DISEASES

Obesity has been recognized as a significant risk factor for retinal vein occlusion in a very limited number of studies.<sup>7,214</sup> In the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Studies (CHS), obese persons were found to have a nearly fourfold increased risk of having retinal vein occlusion, and there was a significant trend of increasing risk across all quartiles of BMI.<sup>214</sup> Moreover, retinal venous and arterial occlusions are known to be associated with hypertension, diabetes mellitus, and hypercoagulability or hyperviscosity syndromes.<sup>122,157,162,214</sup> In addition to the known associations of obesity with hypertension and diabetes, several reviews have presented some evidence supporting the association of hypercoagulability disorders with obesity and metabolic syndrome.<sup>3,151</sup> This provides further support for the possible association between obesity and retinal vascular occlusive diseases.

Other ophthalmic conditions may also be associated with obesity. For example, it has been suggested that obesity may be related to oculomotor nerve palsy.<sup>199</sup> Obesity has also been associated with recurrent lower eyelid entropion.<sup>160</sup> Obstructive sleep apnea syndrome, a common comorbid condition related to obesity, has been associated with papilledema<sup>158</sup> and floppy eyelid syndrome.<sup>139</sup> Moreover, obesity is also a risk factor for benign intracranial hypertension (pseudotumor cerebri).<sup>15,102,163</sup> It has been postulated that central obesity may increase intracranial pressure by increasing intra-abdominal, and subsequently pleural, pressure, with a resultant increase of cardiac filling

pressure, impeding venous return from the brain.<sup>15</sup> This suggestion, however, is not agreed by all investigators.<sup>131</sup> And finally, Prader–Willi syndrome, an obesity-associated condition, was found to be related with a number of ocular abnormalities including myopia, astigmatism, amblyopia, strabismus, and exotropia.<sup>84</sup>

#### Future Research

This review suggests that further research is required to fully understand the relationship between obesity and eye diseases. Several lines of investigation are suggested. First, given the growing epidemic of childhood obesity, the lack of data on the ocular effects of obesity early in life needs to be addressed. Secondly, as this review shows, prospective studies are lacking for many of the associations identified from the cross-sectional data. For example, the associations between obesity and IOP, although consistent, are largely based on cross-sectional data, and there are no studies that show obesity is associated with a demonstrable increase in IOP over time. Third, because obesity is closely related to dietary habits, there is a need to study the effect of dietary risk factors on the association of obesity and eye diseases. Fourth, because the criteria for obesity and the dietary habits varies widely between racial/ethnic groups, further studies are needed to address the potential ocular effects of obesity in different racial/ethnic populations. The association between obesity and ARM is an example where studies have only been conducted in white populations. Fifth, the pathophysiological mechanisms underlying the reported associations identified in the epidemiological studies are unknown, and remain as speculations. Thus, additional experimental, cellular, or molecular studies may broaden our understanding of the impact of obesity on eye health. Sixth, most studies have only provided information about how obesity, defined as BMI, weight, or WHR, relates to the different eye diseases, and the impact of weight change (weight gain or loss) on eye diseases is less clear. Weight change is more clinically relevant and useful in terms of guiding management. Future epidemiological studies should therefore concentrate on the association of weight change and risk of eye diseases. Finally, in contrast to systemic diseases, there are no clinical trials to demonstrate the potential ocular benefits of weight loss. If weight loss is proven to be an effective method, either as a sole or adjuvant treatment, in delaying the onset or slowing the progression of eye diseases in obese individuals, both clinicians and patients will likely gain additional incentive to battle against this major public health problem.

## Conclusion

Obesity is a major public health problem and its impact on ocular health is increasingly recognized. Associations of obesity with cataract, glaucoma, age-related maculopathy, and retinopathy have been reported with varying degree of certainty. The inconsistency of results, combined with the deficiency of robust data, suggest that further investigations are required to clarify these associations. The efficacy of obesity treatment in reducing the risk of eye diseases is also unknown, but studies in this area may provide important insight for the potential use of weight loss strategies to reduce the burden of eye diseases in individuals with obesity.

## Method of Literature Search

A systematic MEDLINE search on National Institute of Health's PubMed (<http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed>) with coverage up to 18 August 2005 was conducted initially using the following keywords *obesity*, *body mass index*, *waist-to-hip ratio*, *weight*, *risk factor* in various combinations with *eye* (368 citations), *eye disease* (725), *ocular* (225), *cataract* (66), *lens opacity* (48), *glaucoma* (37), *intraocular pressure* (32), *maculopathy* (13), *diabetic retinopathy* (24), *hypertensive retinopathy* (34), *retinal arterial occlusion* (8), *retinal venous occlusion* (10). After review of abstracts, relevant articles were retrieved and reviewed. All English articles were read, and for the relevant non-English articles, the English abstracts were reviewed. Bibliographies of these articles provided further references, including books and Internet-based data.

## References

1. \_\_\_\_: Risk factors associated with age-related nuclear and cortical cataract: a case-control study in the Age-Related Eye Disease Study, AREDS Report No. 5. *Ophthalmology* 108:1400–8, 2001
2. \_\_\_\_: Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. *Ophthalmology* 107:2224–32, 2000
3. Abramson N, Abramson S: Hypercoagulability: clinical assessment and treatment. *South Med J* 94:1013–20, 2001
4. Agata J, Masuda A, Takada M, et al: High plasma immunoreactive leptin level in essential hypertension. *Am J Hypertens* 10:1171–4, 1997
5. Aiello LP, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* 331:1480–7, 1994
6. Alam AA, Mitwalli AH, Al-Wakeel JS, et al: Plasma fibrinogen and its correlates in adult Saudi population. *Saudi Med J* 25:1593–602, 2004
7. Backhouse O, Parapia L, Mahomed I, et al: Familial thrombophilia and retinal vein occlusion. *Eye* 14(Pt 1):13–7, 2000
8. Ballard DJ, Melton LJ, Dwyer MS, et al: Risk factors for diabetic retinopathy: a population-based study in Rochester, Minnesota. *Diabetes Care* 9:334–42, 1986
9. Bengtsson B, Heijl A: A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. *J Glaucoma* 14:135–8, 2005
10. Bergman B, Nilsson-Ehle H, Sjöstrand J: Ocular changes, risk markers for eye disorders and effects of cataract surgery in elderly people: a study of an urban Swedish population followed from 70 to 97 years of age. *Acta Ophthalmol Scand* 82:166–74, 2004
11. Bhuyan KC, Bhuyan DK, Podos SM: Lipid peroxidation in cataract of the human. *Life Sci* 38:1463–71, 1986
12. Bianchini F, Kaaks R, Vainio H: Weight control and physical activity in cancer prevention. *Obes Rev* 3:5–8, 2002
13. Bonomi L, Marchini G, Marraffa M, et al: Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. *Ophthalmology* 107:1287–93, 2000
14. Bouloumie A, Marumo T, Lafontan M, et al: Leptin induces oxidative stress in human endothelial cells. *FASEB J* 13:1231–8, 1999
15. Brazis PW, Lee AG: Elevated intracranial pressure and pseudotumor cerebri. *Curr Opin Ophthalmol* 9:27–32, 1998
16. Broadway DC, Drance SM: Glaucoma and vasospasm. *Br J Ophthalmol* 82:862–70, 1998
17. Bulpitt CJ, Hodes C, Everitt MG: Intraocular pressure and systemic blood pressure in the elderly. *Br J Ophthalmol* 59:717–20, 1975
18. Caballero M, Liton PB, Epstein DL, et al: Proteasome inhibition by chronic oxidative stress in human trabecular meshwork cells. *Biochem Biophys Res Commun* 308:346–52, 2003
19. Caldwell RB, Bartoli M, Behzadian MA, et al: Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. *Curr Drug Targets* 6:511–24, 2005
20. Calle EE, Rodriguez C, Walker-Thurmond K, et al: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *N Engl J Med* 348:1625–38, 2003
21. Caulfield LE, West SK, Barrón Y, et al: Anthropometric status and cataract: the Salisbury Eye Evaluation project. *Am J Clin Nutr* 69:237–42, 1999
22. Chatterjee A, Milton RC, Thyle S: Prevalence and aetiology of cataract in Punjab. *Br J Ophthalmol* 66:35–42, 1982
23. Chaturvedi N, Fuller JH: Mortality risk by body weight and weight change in people with NIDDM. The WHO Multinational Study of Vascular Disease in Diabetes. *Diabetes Care* 18:766–74, 1995
24. Chaturvedi N, Sjoelie AK, Porta M, et al: Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. *Diabetes Care* 24:284–9, 2001
25. Chew EY: Diabetic retinopathy and lipid abnormalities. *Curr Opin Ophthalmol* 8:59–62, 1997
26. Chew EY, Klein ML, Ferris FL, et al: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Arch Ophthalmol* 114:1079–84, 1996
27. Chopdar A, Chakravarthy U, Verma D: Age related macular degeneration. *BMJ* 326:485–8, 2003
28. Clemons TE, Milton RC, Klein R, et al: Risk factors for the incidence of Advanced Age-Related Macular Degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. *Ophthalmology* 112:533–9, 2005
29. Cohen RA, Hennekens CH, Christen WG, et al: Determinants of retinopathy progression in type 1 diabetes mellitus. *Am J Med* 107:45–51, 1999
30. Cole TJ, Bellizzi MC, Flegal KM, et al: Establishing a standard definition for child overweight and obesity worldwide: international survey. *BMJ* 320:1240–3, 2000

31. Considine RV, Sinha MK, Heiman ML, et al: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. *N Engl J Med* 334:292-5, 1996
32. Cushman M, Yanez D, Psaty BM, et al: Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. *Am J Epidemiol* 143:665-76, 1996
33. Cusick M, Chew EY, Chan CC, et al: Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels. *Ophthalmology* 110:2126-33, 2003
34. D'Amico DJ, Goldberg MF, Hudson H, et al: Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 110:2372-83, discussion 2384-5, 2003
35. De Block CE, De Leeuw IH, Van Gaal LF: Impact of overweight on chronic microvascular complications in type 1 diabetic patients. *Diabetes Care* 28:1649-55, 2005
36. Delcourt C, Michel F, Colvez A, et al: Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. *Ophthalmic Epidemiol* 8:237-49, 2001
37. Dielemans I, Vingerling JR, Algra D, et al: Primary open-angle glaucoma, intraocular pressure, and systemic blood pressure in the general elderly population. The Rotterdam Study. *Ophthalmology* 102:54-60, 1995
38. Dielemans I, Vingerling JR, Wolfs RC, et al: The prevalence of primary open-angle glaucoma in a population-based study in The Netherlands. The Rotterdam Study. *Ophthalmology* 101:1851-5, 1994
39. Dietz WH: Overweight in childhood and adolescence. *N Engl J Med* 350:855-7, 2004
40. Dorchy H, Claes C, Verougstraete C: Risk factors of developing proliferative retinopathy in type 1 diabetic patients: role of BMI. *Diabetes Care* 25:798-9, 2002
41. Dowse GK, Humphrey AR, Collins VR, et al: Prevalence and risk factors for diabetic retinopathy in the multiethnic population of Mauritius. *Am J Epidemiol* 147:448-57, 1998
42. Duntas LH, Popovic V, Panotopoulos G: Adiponectin: novelties in metabolism and hormonal regulation. *Nutr Neurosci* 7:195-200, 2004
43. Eckel RH, Krauss RM: American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. *Circulation* 97:2099-100, 1998
44. Evereklioglu C, Doganay S, Er H, et al: Serum leptin concentrations are decreased and correlated with disease severity in age-related macular degeneration: a preliminary study. *Eye* 17:350-5, 2003
45. Fasshauer M, Paschke R, Stumvoll M: Adiponectin, obesity, and cardiovascular disease. *Biochimie* 86:779-84, 2004
46. Ferreira SM, Lerner SF, Brunzini R, et al: Oxidative stress markers in aqueous humor of glaucoma patients. *Am J Ophthalmol* 137:62-9, 2004
47. Ferris FL: A new treatment for ocular neovascularization. *N Engl J Med* 351:2863-5, 2004
48. Ferris FL, Chew EY, Hoogwerf BJ: Serum lipids and diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Research Group. *Diabetes Care* 19:1291-3, 1996
49. Flammer F, Orgul S, Costa VP, et al: The impact of ocular blood flow in glaucoma. *Prog Retinal Eye Res* 21:359-93, 2002
50. Flegal KM, Carroll MD, Kuczmarski RJ, et al: Overweight and obesity in the United States: prevalence and trends, 1960-1994. *Int J Obes Relat Metab Disord* 22:39-47, 1998
51. Flegal KM, Carroll MD, Ogden CL, et al: Prevalence and trends in obesity among US adults, 1999-2000. *JAMA* 288:1723-7, 2002
52. Ford ES: Body mass index, diabetes, and C-reactive protein among U.S. adults. *Diabetes Care* 22:1971-7, 1999
53. Foster PJ, Wong TY, Machin D, et al: Risk factors for nuclear, cortical and posterior subcapsular cataracts in the Chinese population of Singapore: the Tanjong Pagar Survey. *Br J Ophthalmol* 87:1112-20, 2003
54. Friedman N, Fanning EL: Overweight and obesity: an overview of prevalence, clinical impact, and economic impact. *Dis Manag* 7(Suppl 1):S1-6, 2004
55. Friedrich MJ: Epidemic of obesity expands its spread to developing countries. *JAMA* 287:1382-6, 2002
56. Frystyk J, Tarnow L, Hansen TK, et al: Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. *Diabetologia* 48:1911-8, 2005
57. Gariano RF, Nath AK, D'Amico DJ, et al: Elevation of vitreous leptin in diabetic retinopathy and retinal detachment. *Invest Ophthalmol Vis Sci* 41:3576-81, 2000
58. Garner MH, Spector A: Selective oxidation of cysteine and methionine in normal and senile cataractous lenses. *Proc Natl Acad Sci USA* 77:1274-7, 1980
59. Garofalo C, Surmacz E: Leptin and cancer. *J Cell Physiol* 207:12-22, 2006
60. Gasser P, Stümpfig D, Schötzau A, et al: Body mass index in glaucoma. *J Glaucoma* 8:8-11, 1999
61. Gherghel D, Griffiths HR, Hilton EJ, et al: Systemic reduction in glutathione levels occurs in patients with primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 46:877-83, 2005
62. Glowńska B, Urban M, Hryniewicz A, et al: Endothelin-1 plasma concentration in children and adolescents with atherogenic risk factors. *Kardiol Pol* 61:329-38, 2004
63. Glynn RJ, Christen WG, Manson JE, et al: Body mass index. An independent predictor of cataract. *Arch Ophthalmol* 113:1131-7, 1995
64. Gómez-Ambrosi J, Salvador J, Frühbeck G: Is hyperleptinemia involved in the development of age-related lens opacities? *Am J Clin Nutr* 79:888-9, author reply 889, 2004
65. Goodrich ME, Cumming RG, Mitchell P, et al: Plasma fibrinogen and other cardiovascular disease risk factors and cataract. *Ophthalmic Epidemiol* 6:279-90, 1999
66. Gordon MO, Beiser JA, Brandt JD, et al: The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol* 120:714-20, discussion 829-30, 2002
67. Gragoudas ES, Adamis AP, Cunningham ET, et al: Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 351:2805-16, 2004
68. Grieshaber MC, Flammer J: Blood flow in glaucoma. *Curr Opin Ophthalmol* 16:79-83, 2005
69. Grundy SM: Metabolic complications of obesity. *Endocrine* 13:155-65, 2000
70. Grunwald JE, Piltz J, Hariprasad SM, et al: Optic nerve and choroidal circulation in glaucoma. *Invest Ophthalmol Vis Sci* 39:2329-36, 1998
71. Hak AE, Stehouwer CD, Bots ML, et al: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. *Arterioscler Thromb Vasc Biol* 19:1986-91, 1999
72. Halpern DL, Grosskreutz CL: Glaucomatous optic neuropathy: mechanisms of disease. *Ophthalmol Clin North Am* 15:61-8, 2002
73. Hankinson SE, Seddon JM, Colditz GA, et al: A prospective study of aspirin use and cataract extraction in women. *Arch Ophthalmol* 111:503-8, 1993
74. Harding JJ: Recent studies of risk factors and protective factors for cataract. *Curr Opin Ophthalmol* 8:46-9, 1997
75. Harris A, Zarfati D, Zalish M, et al: Reduced cerebrovascular blood flow velocities and vasoreactivity in open-angle glaucoma. *Am J Ophthalmol* 135:144-7, 2003
76. Hart PM, Chakravarthy U, Mackenzie G, et al: Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration. *Arch Ophthalmol* 120:1029-38, 2002
77. Haslam DW, James WP: Obesity. *Lancet* 366:1197-209, 2005
78. Hassink SG, Sheslow DV, de Lancey E, et al: Serum leptin in children with obesity: relationship to gender and development. *Pediatrics* 98:201-3, 1996

79. Haynes WG: Role of leptin in obesity-related hypertension. *Exp Physiol* 90:683–8, 2005
80. Haynes WG, Sivitz WI, Morgan DA, et al: Sympathetic and cardiorenal actions of leptin. *Hypertension* 30:619–23, 1997
81. Hedley AA, Ogden CL, Johnson CL, et al: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. *JAMA* 291:2847–50, 2004
82. Hennis A, Wu SY, Nemesure B, et al: Hypertension, diabetes, and longitudinal changes in intraocular pressure. *Ophthalmology* 110:908–14, 2003
83. Henricsson M, Nyström L, Blohmé G, et al: The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). *Diabetes Care* 26:349–54, 2003
84. Hered RW, Rogers S, Zang YF, et al: Ophthalmologic features of Prader–Willi syndrome. *J Pediatr Ophthalmol Strabismus* 25:145–50, 1988
85. Hill JO, Catenacci V, Wyatt HR: Obesity: overview of an epidemic. *Psychiatr Clin North Am* 28:1–23, vii, 2005
86. Hiller R, Podgor MJ, Sperduto RD, et al: A longitudinal study of body mass index and lens opacities. The Framingham Studies. *Ophthalmology* 105:1244–50, 1998
87. Hirvelä H, Luukinen H, Läärä E, et al: Risk factors of age-related maculopathy in a population 70 years of age or older. *Ophthalmology* 103:871–7, 1996
88. Hogg R, Chakravarthy U: AMD and micronutrient antioxidants. *Curr Eye Res* 29:387–401, 2004
89. Holz FG, Pauleikhoff D, Klein R, et al: Pathogenesis of lesions in late age-related macular disease. *Am J Ophthalmol* 137:504–10, 2004
90. Horwitz J: Anatomy and embryology, in Podos SM, Yanoff M (eds): *Textbook of Ophthalmology* 3, Lens and Cataract. New York, Gower Medical Publishing, 1992, pp 50–55
91. Hyman L, Neborsky R: Risk factors for age-related macular degeneration: an update. *Curr Opin Ophthalmol* 13:171–5, 2002
92. Hyman L, Schachat AP, He Q, et al: Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. *Arch Ophthalmol* 118:351–8, 2000
93. Izzotti A, Saccà SC, Cartiglia C, et al: Oxidative deoxyribonucleic acid damage in the eyes of glaucoma patients. *Am J Med* 114:638–46, 2003
94. Jacques PF, Moeller SM, Hankinson SE, et al: Weight status, abdominal adiposity, diabetes, and early age-related lens opacities. *Am J Clin Nutr* 78:400–5, 2003
95. Jaén Díaz J, Sanz Alcolea I, López De Castro F, et al: [Glaucoma and ocular hypertension in primary care]. *Aten Primaria* 28:23–30, 2001
96. Jahn CE, Janke M, Winowski H, et al: Identification of metabolic risk factors for posterior subcapsular cataract. *Ophthalmic Res* 18:112–6, 1986
97. James PT: Obesity: the worldwide epidemic. *Clin Dermatol* 22:276–80, 2004
98. James PT, Leach R, Kalamara E, et al: The worldwide obesity epidemic. *Obes Res* 9(Suppl 4):228S–33S, 2001
99. Jonas JB, Grundler AE, Gonzales-Cortes J, et al: Pressure-dependent neuroretinal rim loss in normal-pressure glaucoma. *Am J Ophthalmol* 125:137–44, 1988
100. Kaiser HJ, Flammer J, Wenk M, et al: Endothelin-1 plasma levels in normal-tension glaucoma: abnormal response to postural changes. *Graefes Arch Clin Exp Ophthalmol* 233:484–8, 1995
101. Karasik A, Modan M, Halkin H, et al: Senile cataract and glucose intolerance: the Israel Study of glucose Intolerance Obesity and Hypertension (The Israel GOH Study). *Diabetes Care* 7:52–6, 1984
102. Kaur H, Hyder ML, Poston WS: Childhood overweight: an expanding problem. *Treat Endocrinol* 2:375–88, 2003
103. Keane JF, Larson MG, Vasan RS, et al: Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. *Arterioscler Thromb Vasc Biol* 23:434–9, 2003
104. Kennedy RL, Chokkalingham K, Srinivasan R: Obesity in the elderly: who should we be treating, and why, and how? *Curr Opin Clin Nutr Metab Care* 7:3–9, 2004
105. Kitazawa Y, Horie T, Aoki S, et al: Untreated ocular hypertension. A long-term prospective study. *Arch Ophthalmol* 95:1180–4, 1977
106. Klein BE, Klein R: Intraocular pressure and cardiovascular risk variables. *Arch Ophthalmol* 99:837–9, 1981
107. Klein BE, Klein R, Lee KE: Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. *Am J Ophthalmol* 126:782–90, 1998
108. Klein BE, Klein R, Lee KE, et al: Measures of obesity and age-related eye diseases. *Ophthalmic Epidemiol* 8:251–62, 2001
109. Klein BE, Klein R, Linton KL: Intraocular pressure in an American community. The Beaver Dam Eye Study. *Invest Ophthalmol Vis Sci* 33:2224–8, 1992
110. Klein BE, Klein R, Moss SE: Incident cataract surgery: the Beaver Dam eye study. *Ophthalmology* 104:573–80, 1997
111. Klein BE, Moss SE, Klein R, et al: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. *Ophthalmology* 98:1261–5, 1991
112. Klein R, Klein BE, Franke T: The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. *Ophthalmology* 100:406–14, 1993
113. Klein R, Klein BE, Moss SE: Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Arch Intern Med* 157:650–6, 1997
114. Klein R, Klein BE, Moss SE, et al: The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. *Arch Ophthalmol* 102:527–32, 1984
115. Klein R, Klein BE, Tomany SC, et al: The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. *Ophthalmology* 110:636–43, 2003
116. Klein R, Peto T, Bird A, et al: The epidemiology of age-related macular degeneration. *Am J Ophthalmol* 137:486–95, 2004
117. Klein R, Sharrett AR, Klein BE, et al: The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. *Ophthalmology* 109:1225–34, 2002
118. Knowler WC, Barrett-Connor E, Fowler SE, et al: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393–403, 2002
119. Kohner EM, Aldington SJ, Stratton IM, et al: United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. *Arch Ophthalmol* 116:297–303, 1998
120. Kopitz J, Holz FG, Kaemmerer E, et al: Lipids and lipid peroxidation products in the pathogenesis of age-related macular degeneration. *Biochimie* 86:825–31, 2004
121. Kuang TM, Tsai SY, Hsu WM, et al: Body mass index and age-related cataract: the Shihpai Eye Study. *Arch Ophthalmol* 123:1109–14, 2005
122. Lahey JM, Kearney JJ, Tunc M: Hypercoagulable states and central retinal vein occlusion. *Curr Opin Pulm Med* 9:385–92, 2003
123. Lawrence VJ, Kopelman PG: Medical consequences of obesity. *Clin Dermatol* 22:296–302, 2004
124. Lee ET, Lee VS, Lu M, et al: Development of proliferative retinopathy in NIDDM. A follow-up study of American Indians in Oklahoma. *Diabetes* 41:359–67, 1992
125. Lee JS, Lee SH, Oum BS, et al: Relationship between intraocular pressure and systemic health parameters in a Korean population. *Clin Experiment Ophthalmol* 30:237–41, 2002

126. Leske MC, Chylack LT, Wu SY: The Lens Opacities Case-Control Study. Risk factors for cataract. *Arch Ophthalmol* 109:244-51, 1991
127. Leske MC, Connell AM, Wu SY, et al: Risk factors for open-angle glaucoma. The Barbados Eye Study. *Arch Ophthalmol* 113:918-24, 1995
128. Leske MC, Podgor MJ: Intraocular pressure, cardiovascular risk variables, and visual field defects. *Am J Epidemiol* 118:280-7, 1983
129. Leske MC, Wu SY, Hennis A, et al: Diabetes, hypertension, and central obesity as cataract risk factors in a black population. The Barbados Eye Study. *Ophthalmology* 106:35-41, 1999
130. Leske MC, Wu SY, Hyman L, et al: Biochemical factors in the lens opacities. Case-control study. The Lens Opacities Case-Control Study Group. *Arch Ophthalmol* 113:1113-9, 1995
131. Lessell S: Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). *Surv Ophthalmol* 37:155-66, 1992
132. Lim HS, MacFadyen RJ, Lip GY: Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. *Arch Intern Med* 164:1737-48, 2004
133. Lobstein T, Baur L, Uauy R, et al: Obesity in children and young people: a crisis in public health. *Obes Rev* 5(Suppl 1):4-104, 2004
134. Maier PC, Funk J, Schwarzer G, et al: Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. *BMJ* 331:134, 2005
135. Mapstone R, Clark CV: Prevalence of diabetes in glaucoma. *Br Med J (Clin Res Ed)* 291:93-5, 1985
136. Marcus DM, Sheils W, Johnson MH, et al: External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. *Arch Ophthalmol* 119:171-80, 2001
137. Matsuda M, Kawasaki F, Yamada K, et al: Impact of adiposity and plasma adipocytokines on diabetic angiopathies in Japanese Type 2 diabetic subjects. *Diabet Med* 21:881-8, 2004
138. McLeod SD, West SK, Quigley HA, et al: A longitudinal study of the relationship between intraocular and blood pressures. *Invest Ophthalmol Vis Sci* 31:2361-6, 1990
139. McNab AA: The eye and sleep. *Clin Experiment Ophthalmol* 33:117-25, 2005
140. Mitchell P, Smith W, Attebo K, et al: Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. *Ophthalmology* 103:1661-9, 1996
141. Mitchell P, Smith W, Chey T, et al: Open-angle glaucoma and diabetes: the Blue Mountains eye study. *Australia. Ophthalmology* 104:712-8, 1997
142. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, et al: Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. *Diabetologia* 46:1483-8, 2003
143. Moeini HA, Masoudpour H, Ghanbari H: A study of the relation between body mass index and the incidence of age related macular degeneration. *Br J Ophthalmol* 89:964-6, 2005
144. Mohan M, Sperduto RD, Angra SK, et al: India-US case-control study of age-related cataracts. India-US Case-Control Study Group. *Arch Ophthalmol* 107:670-6, 1989
145. Moreno MC, Campanelli J, Sande P, et al: Retinal oxidative stress induced by high intraocular pressure. *Free Radic Biol Med* 37:803-12, 2004
146. Mori K, Ando F, Nomura H, et al: Relationship between intraocular pressure and obesity in Japan. *Int J Epidemiol* 29:661-6, 2000
147. Nakamura M, Ishimitsu T, Matsuoka H, et al: [Implications of obesity for target organ injuries and cardiovascular risk factors in hypertensive subjects]. *Nippon Jinzo Gakkai Shi* 39:746-52, 1997
148. Nakamura M, Kanamori A, Negi A: Diabetes mellitus as a risk factor for glaucomatous optic neuropathy. *Ophthalmologica* 219:1-10, 2005
149. Narin F, Atabek ME, Karakukcu M, et al: The association of plasma homocysteine levels with serum leptin and apolipoprotein B levels in childhood obesity. *Ann Saudi Med* 25:209-14, 2005
150. Nelson RG, Wolfe JA, Horton MB, et al: Proliferative retinopathy in NIDDM. Incidence and risk factors in Pima Indians. *Diabetes* 38:435-40, 1989
151. Nieuwdorp M, Stroes ES, Meijers JC, et al: Hypercoagulability in the metabolic syndrome. *Curr Opin Pharmacol* 5:155-9, 2005
152. Oh SW, Lee S, Park C, et al: Elevated intraocular pressure is associated with insulin resistance and metabolic syndrome. *Diabetes Metab Res Rev* 21:434-40, 2005
153. Ohia SE, Opere CA, Leday AM: Pharmacological consequences of oxidative stress in ocular tissues. *Mutat Res* 579:22-36, 2005
154. Olney JW: Inciting excitotoxic cytotoxicity among central neurons. *Adv Exp Med Biol* 203:631-45, 1986
155. Pi-Sunyer FX: Medical hazards of obesity. *Ann Intern Med* 119:655-60, 1993
156. Polak M, Zagórski Z: Lipid peroxidation in diabetic retinopathy. *Ann Univ Mariae Curie Skłodowska [Med]* 59:434-7, 2004
157. Prisco D, Marcucci R: Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. *Pathophysiol Haemost Thromb* 32:308-11, 2002
158. Purvin VA, Kawasaki A, Yee RD: Papilledema and obstructive sleep apnea syndrome. *Arch Ophthalmol* 118:1626-30, 2000
159. Quigley HA, Nickells RW, Kerrigan LA, et al: Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. *Invest Ophthalmol Vis Sci* 36:774-86, 1995
160. Raina J, Foster JA: Obesity as a cause of mechanical entropion. *Am J Ophthalmol* 122:123-5, 1996
161. Ramachandran S, Morris SM, Devamanoharan P, et al: Radio-isotopic determination of hydrogen peroxide in aqueous humor and urine. *Exp Eye Res* 53:503-6, 1991
162. Robinson MK, Halpern JI: Retinal vein occlusion. *Am Fam Physician* 45:2661-6, 1992
163. Rodríguez de Rivera FJ, Martínez-Sánchez P, Ojeda-Ruiz de Luna J, et al: Benign intracranial hypertension. History, clinical features and treatment in a series of 41 patients]. *Rev Neurol* 37:801-5, 115, 2003
164. Roth F, Bindewald A, Holz FG: Key pathophysiologic pathways in age-related macular disease. *Graefes Arch Clin Exp Ophthalmol* 242:710-6, 2004
165. Saccà SC, Pascotto A, Camicione P, et al: Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. *Arch Ophthalmol* 123:458-63, 2005
166. Savinova OV, Sugiyama F, Martin JE, et al: Intraocular pressure in genetically distinct mice: an update and strain survey. *BMC Genet* 2:12, 2001
167. Schaumberg DA, Christen WG, Hankinson SE, et al: Body mass index and the incidence of visually significant age-related maculopathy in men. *Arch Ophthalmol* 119:1259-65, 2001
168. Schaumberg DA, Glynn RJ, Christen WG, et al: Relations of body fat distribution and height with cataract in men. *Am J Clin Nutr* 72:1495-502, 2000
169. Schaumberg DA, Ridker PM, Glynn RJ, et al: High levels of plasma C-reactive protein and future risk of age-related cataract. *Ann Epidemiol* 9:166-71, 1999
170. Schmidt-Erfurth U, Michels S, Michels R, et al: Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Eur J Ophthalmol* 15:482-5, 2005
171. Schoenfeld ER, Leske MC, Wu SY: Recent epidemiologic studies on nutrition and cataract in India, Italy and the United States. *J Am Coll Nutr* 12:521-6, 1993
172. Schorr U, Blaschke K, Turan S, et al: Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. *J Hypertens* 16:1475-80, 1998

173. Seddon JM, Cote J, Davis N, et al: Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. *Arch Ophthalmol* 121:785–92, 2003
174. Sheard NF: Moderate changes in weight and physical activity can prevent or delay the development of type 2 diabetes mellitus in susceptible individuals. *Nutr Rev* 61:76–9, 2003
175. Shiose Y: Intraocular pressure: new perspectives. *Surv Ophthalmol* 34:413–35, 1990
176. Shiose Y: The aging effect on intraocular pressure in an apparently normal population. *Arch Ophthalmol* 102:883–7, 1984
177. Shiose Y, Kawase Y: A new approach to stratified normal intraocular pressure in a general population. *Am J Ophthalmol* 101:714–21, 1986
178. Sierra-Honigmann MR, Nath AK, Murakami C, et al: Biological action of leptin as an angiogenic factor. *Science* 281:1683–6, 1998
179. Silha JV, Krsek M, Sucharda P, et al: Angiogenic factors are elevated in overweight and obese individuals. *Int J Obes (Lond)* 29:1308–14, 2005
180. Sjöström CD, Lissner L, Sjöström L: Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. *Swedish Obese Subjects*. *Obes Res* 5:519–30, 1997
181. Sjöström CD, Lissner L, Wedel H, et al: Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. *Obes Res* 7:477–84, 1999
182. Sjöström L, Lindroos AK, Peltonen M, et al: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med* 351:2683–93, 2004
183. Smith W, Assink J, Klein R, et al: Risk factors for age-related macular degeneration: Pooled findings from three continents. *Ophthalmology* 108:697–704, 2001
184. Smith W, Mitchell P, Leeder SR, et al: Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. *Arch Ophthalmol* 116:583–7, 1998
185. Sommer A: Intraocular pressure and glaucoma. *Am J Ophthalmol* 107:186–8, 1989
186. Spaide RF, Armstrong D, Browne R: Continuing medical education review: choroidal neovascularization in age-related macular degeneration—what is the cause? *Retina* 23:595–614, 2003
187. Spector A: Oxidative stress-induced cataract: mechanism of action. *FASEB J* 9:1173–82, 1995
188. Spector A, Garner WH: Hydrogen peroxide and human cataract. *Exp Eye Res* 33:673–81, 1981
189. Spector A, Wang GM, Wang RR: The prevention of cataract caused by oxidative stress in cultured rat lenses. II. Early effects of photochemical stress and recovery. *Exp Eye Res* 57:659–67, 1993
190. Spector A, Wang GM, Wang RR, et al: A brief photochemically induced oxidative insult causes irreversible lens damage and cataract. II. Mechanism of action. *Exp Eye Res* 60:483–93, 1995
191. Stevens VJ, Obarzanek E, Cook NR, et al: Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. *Ann Intern Med* 134:1–11, 2001
192. Stratton IM, Kohner EM, Aldington SJ, et al: UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia* 44:156–63, 2001
193. Su DH, Yeo KT: Diabetic retinopathy and serum lipids. *Singapore Med J* 41:295–7, 2000
194. Suter PM, Locher R, Hasler E, et al: Is there a role for the ob gene product leptin in essential hypertension? *Am J Hypertens* 11:1305–11, 1998
195. Tamburrino MB, McGinnis RA: Anorexia nervosa. A review. *Panminerva Med* 44:301–11, 2002
196. Tapp RJ, Shaw JE, Harper CA, et al: The prevalence of and factors associated with diabetic retinopathy in the Australian population. *Diabetes Care* 26:1731–7, 2003
197. Tavani A, Negri E, La Vecchia C: Selected diseases and risk of cataract in women. A case-control study from northern Italy. *Ann Epidemiol* 5:234–8, 1995
198. Taylor A: Nutritional influences on risk for cataract. *Int Ophthalmol Clin* 40:17–49, 2000
199. Teuscher AU, Meienberg O: Ischaemic oculomotor nerve palsy. Clinical features and vascular risk factors in 23 patients. *J Neurol* 232:144–9, 1985
200. Tielsch JM, Katz J, Sommer A, et al: Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. *Arch Ophthalmol* 113:216–21, 1995
201. Torgerson JS, Hauptman J, Boldrin MN, et al: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* 27:155–61, 2004
202. Tuomilehto J, Lindström J, Eriksson JG, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 344:1343–50, 2001
203. Uckaya G, Ozata M, Bayraktar Z, et al: Is leptin associated with diabetic retinopathy? *Diabetes Care* 23:371–6, 2000
204. Uckaya G, Ozata M, Sonmez A, et al: Is leptin associated with hypertensive retinopathy? *J Clin Endocrinol Metab* 85:683–7, 2000
205. Ughade SN, Zodpey SP, Khanolkar VA: Risk factors for cataract: a case control study. *Indian J Ophthalmol* 46:221–7, 1998
206. Valle V, Martos R, Gascon F, et al: Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. *Diabetes Metab* 31:55–62, 2005
207. van Leiden HA, Dekker JM, Moll AC, et al: Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. *Diabetes Care* 25:1320–5, 2002
208. van Leiden HA, Dekker JM, Moll AC, et al: Risk factors for incident retinopathy in a diabetic and nondiabetic population: the Hoorn study. *Arch Ophthalmol* 121:245–51, 2003
209. Visser M, Bouter LM, McQuillan GM, et al: Elevated C-reactive protein levels in overweight and obese adults. *JAMA* 282:2131–5, 1999
210. Wachter A, Sun Y, Dasch B, et al: Münster age- and retina study (MARS). Association between risk factors for arteriosclerosis and age-related macular degeneration. *Ophthalmologie* 101:50–3, 2004
211. Weintraub JM, Willett WC, Rosner B, et al: A prospective study of the relationship between body mass index and cataract extraction among US women and men. *Int J Obes Relat Metab Disord* 26:1588–95, 2002
212. West SK, Valmadrid CT: Epidemiology of risk factors for age-related cataract. *Surv Ophthalmol* 39:323–34, 1995
213. Wong TY, Duncan BB, Golden SH, et al: Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk in Communities study. *Invest Ophthalmol Vis Sci* 45:2949–54, 2004
214. Wong TY, Larsen EK, Klein R, et al: Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities and Cardiovascular Health studies. *Ophthalmology* 112:540–7, 2005
215. Wong TY, Mitchell P: Hypertensive retinopathy. *N Engl J Med* 351:2310–7, 2004
216. Wood PD, Stefanick ML, Dreon DM, et al: Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. *N Engl J Med* 319:1173–9, 1988
217. Wormald R, Evans J, Smeeth L, et al: Photodynamic therapy for neovascular age-related macular degeneration. *Cochrane Database Syst Rev* 4. CD002030, 2005

218. Wu SY, Leske MC: Associations with intraocular pressure in the Barbados Eye Study. *Archives of Ophthalmology* 115: 1572–6, 1997
219. Yamagishi S, Amano S, Inagaki Y, et al: Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. *Microvasc Res* 65:186–90, 2003
220. Yilmaz MI, Sonmez A, Acikel C, et al: Adiponectin may play a part in the pathogenesis of diabetic retinopathy. *Eur J Endocrinol* 151:135–40, 2004
221. Yoshida M, Ishikawa M, Kokaze A, et al: Association of lifestyle with intraocular pressure in middle-aged and older Japanese residents. *Jpn J Ophthalmol* 47:191–8, 2003
222. Younan C, Mitchell P, Cumming R, et al: Cardiovascular disease, vascular risk factors and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. *Ophthalmic Epidemiol* 10:227–40, 2003
223. Yudkin JS, Eringa E, Stehouwer CD: Vasocrine” signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. *Lancet* 365:1817–20, 2005
224. Zanella MT, Kohlmann O, Ribeiro AB: Treatment of obesity hypertension and diabetes syndrome. *Hypertension* 38:705–8, 2001
225. Zang EA, Wynder EL: The association between body mass index and the relative frequencies of diseases in a sample of hospitalized patients. *Nutr Cancer* 21:247–61, 1994
226. Zarbin MA: Current concepts in the pathogenesis of age-related macular degeneration. *Arch Ophthalmol* 122:598–614, 2004
227. Zhang F, Chen Y, Heiman M, et al: Leptin: structure, function and biology. *Vitam Horm* 71:345–72, 2005
228. Zhang L, Krzentowski G, Albert A, et al: Risk of developing retinopathy in Diabetes Control and Complications Trial type I diabetic patients with good or poor metabolic control. *Diabetes Care* 24:1275–9, 2001
229. Zhou L, Li Y, Yue BY: Oxidative stress affects cytoskeletal structure and cell-matrix interactions in cells from an ocular tissue: the trabecular meshwork. *J Cell Physiol* 180: 182–9, 1999

---

This article was partially funded by NIH grant R21-HL077166, the Science, Technology Innovation (STI) Grant and the Sylvia and Charles Viertel Clinical Investigator Award, Australia (TYW). The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this review.

Reprint address: Tien Y. Wong, MD, PhD, Retinal Vascular Imaging Centre, Centre for Eye Research Australia, University of Melbourne, 32 Gisborne Street, East Melbourne 3002, AUSTRALIA.